1
|
Iwata T, Kousa T, Nishioka Y, Ohwada K, Sumida K, Annese E, Kakoki M, Kuroda K, Iwasawa H, Arita M, Kumar S, Kimura A, Miyamoto K, Okuda T. Laser-based angle-resolved photoemission spectroscopy with micrometer spatial resolution and detection of three-dimensional spin vector. Sci Rep 2024; 14:127. [PMID: 38177136 PMCID: PMC10766951 DOI: 10.1038/s41598-023-47719-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2023] [Accepted: 11/17/2023] [Indexed: 01/06/2024] Open
Abstract
We have developed a state-of-the-art apparatus for laser-based spin- and angle-resolved photoemission spectroscopy with micrometer spatial resolution (µ-SARPES). This equipment is realized by the combination of a high-resolution photoelectron spectrometer, a 6 eV laser with high photon flux that is focused down to a few micrometers, a high-precision sample stage control system, and a double very-low-energy-electron-diffraction spin detector. The setup achieves an energy resolution of 1.5 (5.5) meV without (with) the spin detection mode, compatible with a spatial resolution better than 10 µm. This enables us to probe both spatially-resolved electronic structures and vector information of spin polarization in three dimensions. The performance of µ-SARPES apparatus is demonstrated by presenting ARPES and SARPES results from topological insulators and Au photolithography patterns on a Si (001) substrate.
Collapse
Affiliation(s)
- Takuma Iwata
- Graduate School of Advanced Science and Engineering, Hiroshima University, 1-3-1 Kagamiyama, Higashi-Hiroshima, 739-8526, Japan
- International Institute for Sustainability with Knotted Chiral Meta Matter (WPI-SKCM2), Hiroshima University, Higashi-hiroshima, 739-8526, Japan
| | - T Kousa
- Graduate School of Advanced Science and Engineering, Hiroshima University, 1-3-1 Kagamiyama, Higashi-Hiroshima, 739-8526, Japan
| | - Y Nishioka
- Graduate School of Advanced Science and Engineering, Hiroshima University, 1-3-1 Kagamiyama, Higashi-Hiroshima, 739-8526, Japan
| | - K Ohwada
- Graduate School of Advanced Science and Engineering, Hiroshima University, 1-3-1 Kagamiyama, Higashi-Hiroshima, 739-8526, Japan
| | - K Sumida
- Materials Sciences Research Center, Japan Atomic Energy Agency, Sayo-gun, Hyogo, 679-5148, Japan
- Hiroshima Synchrotron Radiation Center, Hiroshima University, 2-313 Kagamiyama, Higashi-Hiroshima, 739-0046, Japan
| | - E Annese
- Brazilian Center for Research in Physics, Rua Dr. Xavier Sigaud 150, Rio de Janeiro, RJ, 22290-180, Brazil
| | - M Kakoki
- Graduate School of Advanced Science and Engineering, Hiroshima University, 1-3-1 Kagamiyama, Higashi-Hiroshima, 739-8526, Japan
| | - Kenta Kuroda
- Graduate School of Advanced Science and Engineering, Hiroshima University, 1-3-1 Kagamiyama, Higashi-Hiroshima, 739-8526, Japan.
- International Institute for Sustainability with Knotted Chiral Meta Matter (WPI-SKCM2), Hiroshima University, Higashi-hiroshima, 739-8526, Japan.
| | - H Iwasawa
- Institute for Advanced Synchrotron Light Source, National Institutes for Quantum Science and Technology, Sendai, 980-8579, Japan
- Synchrotron Radiation Research Center, National Institutes for Quantum Science and Technology, Hyogo, 679-5148, Japan
- Hiroshima Synchrotron Radiation Center, Hiroshima University, 2-313 Kagamiyama, Higashi-Hiroshima, 739-0046, Japan
| | - M Arita
- Hiroshima Synchrotron Radiation Center, Hiroshima University, 2-313 Kagamiyama, Higashi-Hiroshima, 739-0046, Japan
| | - S Kumar
- Hiroshima Synchrotron Radiation Center, Hiroshima University, 2-313 Kagamiyama, Higashi-Hiroshima, 739-0046, Japan
| | - A Kimura
- Graduate School of Advanced Science and Engineering, Hiroshima University, 1-3-1 Kagamiyama, Higashi-Hiroshima, 739-8526, Japan
- International Institute for Sustainability with Knotted Chiral Meta Matter (WPI-SKCM2), Hiroshima University, Higashi-hiroshima, 739-8526, Japan
| | - K Miyamoto
- Hiroshima Synchrotron Radiation Center, Hiroshima University, 2-313 Kagamiyama, Higashi-Hiroshima, 739-0046, Japan
| | - T Okuda
- Hiroshima Synchrotron Radiation Center, Hiroshima University, 2-313 Kagamiyama, Higashi-Hiroshima, 739-0046, Japan
| |
Collapse
|
2
|
Joliat GR, de Man R, Rijckborst V, Cimino M, Torzilli G, Choi GH, Lee HS, Goh B, Kokudo T, Shirata C, Hasegawa K, Nishioka Y, Vauthey JN, Baimas-George M, Vrochides D, Demartines N, Halkic N, Labgaa I. Long-term outcomes of ruptured hepatocellular carcinoma: An international multicentric propensity score-matched study. Br J Surg 2022. [DOI: 10.1093/bjs/znac178.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
Abstract
Objective
Long-term outcomes of patients with ruptured hepatocellular carcinoma (rHCC) remain scant. This study aimed to assess disease-free survival (DFS) and overall survival (OS) after surgical resection of rHCC compared to non-ruptured HCC (nrHCC).
Methods
Patients with rHCC and nrHCC were collected from 8 centers in Europe, Asia, and North America. Resected rHCC patients were matched 1:1 to patients undergoing surgery for nrHCC using propensity score and nearest-neighbor method (matching criteria: age, tumor size, cirrhosis, Child-Pugh score, Barcelona Clinic Liver Cancer stage, resection status, grade, and microvascular invasion). Survival rates were calculated using Kaplan-Meier method.
Results
A total of 2033 patients were included: 226 rHCC patients (172 operated: 68 with upfront surgery and 104 after embolization) and 1807 nrHCC patients. Median DFS and OS of rHCC patients (all treatments confounded) were 10 months (95% CI 7–13) and 22 months (95% CI 13–31). Prognostic factors for worse OS among rHCC patients were absence of preoperative arterial embolization (HR 2.3, 95% CI 1.2–4.6, p=0.016), cirrhosis Child B/C (HR 2.4, 95% CI 1.1–5.4, p=0.040), and R1/R2 margins (HR 2, 95% CI 1–5, p=0.049). Survivals were similar between Western and Eastern rHCC patients.
After propensity score matching, 106 rHCC patients and 106 nrHCC patients displayed similar characteristics. Patients with rHCC had shorter median DFS (12 months, 95% CI 7–17 vs. 22 months, 95% CI 12–32, p=0.011), but similar median OS compared to nrHCC patients (43 months, 95% CI 21–65 vs. 63 months, 95% CI 21–105, p=0.060).
Conclusion
In this large dataset including Eastern and Western patients, rHCC was associated with shorter DFS compared to nrHCC, while OS was similar.
Collapse
Affiliation(s)
- G-R Joliat
- Department of Visceral Surgery, Lausanne University Hospital , Lausanne, Switzerland
| | - R de Man
- Department of Gastroenterology and Hepatology, Erasmus Medical Center , Rotterdam, The Netherlands
| | - V Rijckborst
- Department of Gastroenterology and Hepatology, Erasmus Medical Center , Rotterdam, The Netherlands
| | - M Cimino
- Department of General and Minimally Invasive Surgery, Humanitas Clinical and Research Hospital , Milan, Italy
| | - G Torzilli
- Department of General and Minimally Invasive Surgery, Humanitas Clinical and Research Hospital , Milan, Italy
| | - G H Choi
- Department of Surgery, Yonsei University College of Medicine , Seoul, South Korea
| | - H S Lee
- Department of Surgery, Yonsei University College of Medicine , Seoul, South Korea
| | - B Goh
- Department of Surgery, Singapore General Hospital , Singapore, Singapore
| | - T Kokudo
- Department of Surgery, The University of Tokyo Hospital , Tokyo, Japan
| | - C Shirata
- Department of Surgery, The University of Tokyo Hospital , Tokyo, Japan
- Department of Visceral Surgery, Lausanne University Hospital , Lausanne, Switzerland
| | - K Hasegawa
- Department of Surgery, The University of Tokyo Hospital , Tokyo, Japan
| | - Y Nishioka
- Department of Surgical Oncology, MD Anderson Cancer Center , Houston, USA
| | - J-N Vauthey
- Department of Surgical Oncology, MD Anderson Cancer Center , Houston, USA
| | - M Baimas-George
- Department of Surgery, Atrium Health, Carolinas Medical Center , Charlotte, USA
| | - D Vrochides
- Department of Surgery, Atrium Health, Carolinas Medical Center , Charlotte, USA
| | - N Demartines
- Department of Visceral Surgery, Lausanne University Hospital , Lausanne, Switzerland
| | - N Halkic
- Department of Visceral Surgery, Lausanne University Hospital , Lausanne, Switzerland
| | - I Labgaa
- Department of Visceral Surgery, Lausanne University Hospital , Lausanne, Switzerland
| |
Collapse
|
3
|
Yamazaki R, Matsukiyo S, Morita T, Tanaka SJ, Umeda T, Aihara K, Edamoto M, Egashira S, Hatsuyama R, Higuchi T, Hihara T, Horie Y, Hoshino M, Ishii A, Ishizaka N, Itadani Y, Izumi T, Kambayashi S, Kakuchi S, Katsuki N, Kawamura R, Kawamura Y, Kisaka S, Kojima T, Konuma A, Kumar R, Minami T, Miyata I, Moritaka T, Murakami Y, Nagashima K, Nakagawa Y, Nishimoto T, Nishioka Y, Ohira Y, Ohnishi N, Ota M, Ozaki N, Sano T, Sakai K, Sei S, Shiota J, Shoji Y, Sugiyama K, Suzuki D, Takagi M, Toda H, Tomita S, Tomiya S, Yoneda H, Takezaki T, Tomita K, Kuramitsu Y, Sakawa Y. High-power laser experiment forming a supercritical collisionless shock in a magnetized uniform plasma at rest. Phys Rev E 2022; 105:025203. [PMID: 35291161 DOI: 10.1103/physreve.105.025203] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2020] [Accepted: 01/19/2022] [Indexed: 06/14/2023]
Abstract
We present an experimental method to generate quasiperpendicular supercritical magnetized collisionless shocks. In our experiment, ambient nitrogen (N) plasma is at rest and well magnetized, and it has uniform mass density. The plasma is pushed by laser-driven ablation aluminum (Al) plasma. Streaked optical pyrometry and spatially resolved laser collective Thomson scattering clarify structures of plasma density and temperatures, which are compared with one-dimensional particle-in-cell simulations. It is indicated that just after the laser irradiation, the Al plasma is magnetized by a self-generated Biermann battery field, and the plasma slaps the incident N plasma. The compressed external field in the N plasma reflects N ions, leading to counterstreaming magnetized N flows. Namely, we identify the edge of the reflected N ions. Such interacting plasmas form a magnetized collisionless shock.
Collapse
Affiliation(s)
- R Yamazaki
- Department of Physical Sciences, Aoyama Gakuin University, 5-10-1 Fuchinobe, Sagamihara, Kanagawa 252-5258, Japan
- Institute of Laser Engineering, Osaka University, 2-6, Yamadaoka, Suita, Osaka 565-0871, Japan
| | - S Matsukiyo
- Faculty of Engineering Sciences, Kyushu University, 6-1 Kasuga-Koen, Kasuga, Fukuoka 816-8580, Japan
| | - T Morita
- Faculty of Engineering Sciences, Kyushu University, 6-1 Kasuga-Koen, Kasuga, Fukuoka 816-8580, Japan
| | - S J Tanaka
- Department of Physical Sciences, Aoyama Gakuin University, 5-10-1 Fuchinobe, Sagamihara, Kanagawa 252-5258, Japan
| | - T Umeda
- Institute for Space-Earth Environmental Research, Nagoya University, Furo-cho, Chikusa, Nagoya, Aichi 464-8602, Japan
| | - K Aihara
- Department of Physical Sciences, Aoyama Gakuin University, 5-10-1 Fuchinobe, Sagamihara, Kanagawa 252-5258, Japan
| | - M Edamoto
- Interdisciplinary Graduate School of Engineering Sciences, Kyushu University, Kasuga 816-8580, Japan
| | - S Egashira
- Graduate School of Science, Osaka University, 1-1 Machikane-yama, Toyonaka, Osaka 560-0043, Japan
| | - R Hatsuyama
- Interdisciplinary Graduate School of Engineering Sciences, Kyushu University, Kasuga 816-8580, Japan
| | - T Higuchi
- Interdisciplinary Graduate School of Engineering Sciences, Kyushu University, Kasuga 816-8580, Japan
| | - T Hihara
- Graduate School of Engineering, Osaka University, 2-1, Yamadaoka, Suita, Osaka 565-0871, Japan
| | - Y Horie
- Interdisciplinary Graduate School of Engineering Sciences, Kyushu University, Kasuga 816-8580, Japan
| | - M Hoshino
- Department of Earth and Planetary Science, University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - A Ishii
- Max Planck Institute for Gravitational Physics (Albert Einstein Institute), Am Mühlenberg 1, Potsdam-Golm 14476, Germany
| | - N Ishizaka
- Department of Physical Sciences, Aoyama Gakuin University, 5-10-1 Fuchinobe, Sagamihara, Kanagawa 252-5258, Japan
| | - Y Itadani
- Interdisciplinary Graduate School of Engineering Sciences, Kyushu University, Kasuga 816-8580, Japan
| | - T Izumi
- Graduate School of Science, Osaka University, 1-1 Machikane-yama, Toyonaka, Osaka 560-0043, Japan
| | - S Kambayashi
- Department of Physical Sciences, Aoyama Gakuin University, 5-10-1 Fuchinobe, Sagamihara, Kanagawa 252-5258, Japan
| | - S Kakuchi
- Department of Physical Sciences, Aoyama Gakuin University, 5-10-1 Fuchinobe, Sagamihara, Kanagawa 252-5258, Japan
| | - N Katsuki
- Interdisciplinary Graduate School of Engineering Sciences, Kyushu University, Kasuga 816-8580, Japan
| | - R Kawamura
- Department of Physical Sciences, Aoyama Gakuin University, 5-10-1 Fuchinobe, Sagamihara, Kanagawa 252-5258, Japan
| | - Y Kawamura
- Department of Physical Sciences, Aoyama Gakuin University, 5-10-1 Fuchinobe, Sagamihara, Kanagawa 252-5258, Japan
| | - S Kisaka
- Department of Physical Science, Hiroshima University, Higashi-Hiroshima 739-8526, Japan
| | - T Kojima
- Interdisciplinary Graduate School of Engineering Sciences, Kyushu University, Kasuga 816-8580, Japan
| | - A Konuma
- Institute for Laser Science, University of Electro-Communications, 1-5-1 Chofugaoka, Chofu, Tokyo 182-8585, Japan
| | - R Kumar
- Graduate School of Science, Osaka University, 1-1 Machikane-yama, Toyonaka, Osaka 560-0043, Japan
| | - T Minami
- Graduate School of Engineering, Osaka University, 2-1, Yamadaoka, Suita, Osaka 565-0871, Japan
| | - I Miyata
- Department of Physical Sciences, Aoyama Gakuin University, 5-10-1 Fuchinobe, Sagamihara, Kanagawa 252-5258, Japan
| | - T Moritaka
- Fundamental Physics Simulation Research Division, National Institute for Fusion Science, 322-6 Oroshi-cho, Toki 509-5292, Japan
| | - Y Murakami
- Interdisciplinary Graduate School of Engineering Sciences, Kyushu University, Kasuga 816-8580, Japan
| | - K Nagashima
- Interdisciplinary Graduate School of Engineering Sciences, Kyushu University, Kasuga 816-8580, Japan
| | - Y Nakagawa
- Graduate School of Science, Osaka University, 1-1 Machikane-yama, Toyonaka, Osaka 560-0043, Japan
| | - T Nishimoto
- School of Engineering, Osaka University, 2-1, Yamadaoka, Suita, Osaka 565-0871, Japan
| | - Y Nishioka
- Interdisciplinary Graduate School of Engineering Sciences, Kyushu University, Kasuga 816-8580, Japan
| | - Y Ohira
- Department of Earth and Planetary Science, University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - N Ohnishi
- Department of Aerospace Engineering, Tohoku University, 6-6 Aramaki Aza Aoba, Aoba, Sendai, Miyagi 980-8579, Japan
| | - M Ota
- Graduate School of Science, Osaka University, 1-1 Machikane-yama, Toyonaka, Osaka 560-0043, Japan
| | - N Ozaki
- Graduate School of Engineering, Osaka University, 2-1, Yamadaoka, Suita, Osaka 565-0871, Japan
| | - T Sano
- Institute of Laser Engineering, Osaka University, 2-6, Yamadaoka, Suita, Osaka 565-0871, Japan
| | - K Sakai
- Graduate School of Engineering, Osaka University, 2-1, Yamadaoka, Suita, Osaka 565-0871, Japan
| | - S Sei
- Department of Physical Sciences, Aoyama Gakuin University, 5-10-1 Fuchinobe, Sagamihara, Kanagawa 252-5258, Japan
| | - J Shiota
- Department of Physical Sciences, Aoyama Gakuin University, 5-10-1 Fuchinobe, Sagamihara, Kanagawa 252-5258, Japan
| | - Y Shoji
- Department of Physical Sciences, Aoyama Gakuin University, 5-10-1 Fuchinobe, Sagamihara, Kanagawa 252-5258, Japan
| | - K Sugiyama
- Department of Physical Sciences, Aoyama Gakuin University, 5-10-1 Fuchinobe, Sagamihara, Kanagawa 252-5258, Japan
| | - D Suzuki
- Department of Physical Sciences, Aoyama Gakuin University, 5-10-1 Fuchinobe, Sagamihara, Kanagawa 252-5258, Japan
| | - M Takagi
- Interdisciplinary Graduate School of Engineering Sciences, Kyushu University, Kasuga 816-8580, Japan
| | - H Toda
- Department of Physical Sciences, Aoyama Gakuin University, 5-10-1 Fuchinobe, Sagamihara, Kanagawa 252-5258, Japan
| | - S Tomita
- Astronomical Institute, Tohoku University, 6-3 Aramaki, Aoba-ku, Sendai, Miyagi 980-8578, Japan
- Frontier Research Institute for Interdisciplinary Sciences, Tohoku University, Sendai 980-8578, Japan
| | - S Tomiya
- Department of Physical Sciences, Aoyama Gakuin University, 5-10-1 Fuchinobe, Sagamihara, Kanagawa 252-5258, Japan
| | - H Yoneda
- Institute for Laser Science, University of Electro-Communications, 1-5-1 Chofugaoka, Chofu, Tokyo 182-8585, Japan
| | - T Takezaki
- Department of Creative Engineering, National Institute of Technology, Kitakyushu College, 5-20-1 Shii, Kokuraminamiku, Kitakyushu, Fukuoka 802-0985, Japan
- Faculty of Engineering, University of Toyama, 3190, Gofuku, Toyama 930-8555, Japan
| | - K Tomita
- Faculty of Engineering Sciences, Kyushu University, 6-1 Kasuga-Koen, Kasuga, Fukuoka 816-8580, Japan
- Division of Quantum Science and Engineering, Hokkaido University, Sapporo 060-8628, Japan
| | - Y Kuramitsu
- Graduate School of Engineering, Osaka University, 2-1, Yamadaoka, Suita, Osaka 565-0871, Japan
| | - Y Sakawa
- Institute of Laser Engineering, Osaka University, 2-6, Yamadaoka, Suita, Osaka 565-0871, Japan
| |
Collapse
|
4
|
Kawaguchi Y, Kopetz S, Tran Cao HS, Panettieri E, De Bellis M, Nishioka Y, Hwang H, Wang X, Tzeng CWD, Chun YS, Aloia TA, Hasegawa K, Guglielmi A, Giuliante F, Vauthey JN. Contour prognostic model for predicting survival after resection of colorectal liver metastases: development and multicentre validation study using largest diameter and number of metastases with RAS mutation status. Br J Surg 2021; 108:968-975. [PMID: 33829254 DOI: 10.1093/bjs/znab086] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2020] [Revised: 09/18/2020] [Accepted: 02/11/2021] [Indexed: 12/13/2022]
Abstract
BACKGROUND Most current models for predicting survival after resection of colorectal liver metastasis include largest diameter and number of colorectal liver metastases as dichotomous variables, resulting in underestimation of the extent of risk variation and substantial loss of statistical power. The aim of this study was to develop and validate a new prognostic model for patients undergoing liver resection including largest diameter and number of colorectal liver metastases as continuous variables. METHODS A prognostic model was developed using data from patients who underwent liver resection for colorectal liver metastases at MD Anderson Cancer Center and had RAS mutational data. A Cox proportional hazards model analysis was used to develop a model based on largest colorectal liver metastasis diameter and number of metastases as continuous variables. The model results were shown using contour plots, and validated externally in an international multi-institutional cohort. RESULTS A total of 810 patients met the inclusion criteria. Largest colorectal liver metastasis diameter (hazard ratio (HR) 1.11, 95 per cent confidence interval 1.06 to 1.16; P < 0.001), number of colorectal liver metastases (HR 1.06, 1.03 to 1.09; P < 0.001), and RAS mutation status (HR 1.76, 1.42 to 2.18; P < 0.001) were significantly associated with overall survival, together with age, primary lymph node metastasis, and prehepatectomy chemotherapy. The model performed well in the external validation cohort, with predicted overall survival values almost lying within 10 per cent of observed values. Wild-type RAS was associated with better overall survival than RAS mutation even when liver resection was performed for larger and/or multiple colorectal liver metastases. CONCLUSION The contour prognostic model, based on diameter and number of lesions considered as continuous variables along with RAS mutation, predicts overall survival after resection of colorectal liver metastasis.
Collapse
Affiliation(s)
- Y Kawaguchi
- Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.,Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan
| | - S Kopetz
- Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - H S Tran Cao
- Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - E Panettieri
- Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.,Hepatobiliary Surgery Unit, Foundation and Teaching Hospital IRCCS A. Gemelli, Rome, Italy
| | - M De Bellis
- Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.,Department of Surgery, Division of General and Hepatobiliary Surgery, G. B. Rossi University Hospital, University of Verona, Verona, Italy
| | - Y Nishioka
- Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan
| | - H Hwang
- Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - X Wang
- Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - C-W D Tzeng
- Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Y S Chun
- Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - T A Aloia
- Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - K Hasegawa
- Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan
| | - A Guglielmi
- Department of Surgery, Division of General and Hepatobiliary Surgery, G. B. Rossi University Hospital, University of Verona, Verona, Italy
| | - F Giuliante
- Hepatobiliary Surgery Unit, Foundation and Teaching Hospital IRCCS A. Gemelli, Rome, Italy
| | - J-N Vauthey
- Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| |
Collapse
|
5
|
Wells AU, Flaherty KR, Brown KK, Inoue Y, Devaraj A, Richeldi L, Moua T, Crestani B, Wuyts WA, Stowasser S, Quaresma M, Goeldner RG, Schlenker-Herceg R, Kolb M, Aburto M, Acosta O, Andrews C, Antin-Ozerkis D, Arce G, Arias M, Avdeev S, Barczyk A, Bascom R, Bazdyrev E, Beirne P, Belloli E, Bergna M, Bergot E, Bhatt N, Blaas S, Bondue B, Bonella F, Britt E, Buch K, Burk J, Cai H, Cantin A, Castillo Villegas D, Cazaux A, Cerri S, Chaaban S, Chaudhuri N, Cottin V, Crestani B, Criner G, Dahlqvist C, Danoff S, Dematte D'Amico J, Dilling D, Elias P, Ettinger N, Falk J, Fernández Pérez E, Gamez-Dubuis A, Giessel G, Gifford A, Glassberg M, Glazer C, Golden J, Gómez Carrera L, Guiot J, Hallowell R, Hayashi H, Hetzel J, Hirani N, Homik L, Hope-Gill B, Hotchkin D, Ichikado K, Ilkovich M, Inoue Y, Izumi S, Jassem E, Jones L, Jouneau S, Kaner R, Kang J, Kawamura T, Kessler R, Kim Y, Kishi K, Kitamura H, Kolb M, Kondoh Y, Kono C, Koschel D, Kreuter M, Kulkarni T, Kus J, Lebargy F, León Jiménez A, Luo Q, Mageto Y, Maher T, Makino S, Marchand-Adam S, Marquette C, Martinez R, Martínez M, Maturana Rozas R, Miyazaki Y, Moiseev S, Molina-Molina M, Morrison L, Morrow L, Moua T, Nambiar A, Nishioka Y, Nunes H, Okamoto M, Oldham J, Otaola M, Padilla M, Park J, Patel N, Pesci A, Piotrowski W, Pitts L, Poonyagariyagorn H, Prasse A, Quadrelli S, Randerath W, Refini R, Reynaud-Gaubert M, Riviere F, Rodríguez Portal J, Rosas I, Rossman M, Safdar Z, Saito T, Sakamoto N, Salinas Fénero M, Sauleda J, Schmidt S, Scholand M, Schwartz M, Shapera S, Shlobin O, Sigal B, Silva Orellana A, Skowasch D, Song J, Stieglitz S, Stone H, Strek M, Suda T, Sugiura H, Takahashi H, Takaya H, Takeuchi T, Thavarajah K, Tolle L, Tomassetti S, Tomii K, Valenzuela C, Vancheri C, Varone F, Veeraraghavan S, Villar A, Weigt S, Wemeau L, Wuyts W, Xu Z, Yakusevich V, Yamada Y, Yamauchi H, Ziora D. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med 2020; 8:453-460. [PMID: 32145830 DOI: 10.1016/s2213-2600(20)30036-9] [Citation(s) in RCA: 263] [Impact Index Per Article: 65.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/18/2019] [Revised: 01/06/2020] [Accepted: 01/16/2020] [Indexed: 12/20/2022]
Abstract
BACKGROUND The INBUILD trial investigated the efficacy and safety of nintedanib versus placebo in patients with progressive fibrosing interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis (IPF). We aimed to establish the effects of nintedanib in subgroups based on ILD diagnosis. METHODS The INBUILD trial was a randomised, double-blind, placebo-controlled, parallel group trial done at 153 sites in 15 countries. Participants had an investigator-diagnosed fibrosing ILD other than IPF, with chest imaging features of fibrosis of more than 10% extent on high resolution CT (HRCT), forced vital capacity (FVC) of 45% or more predicted, and diffusing capacity of the lung for carbon monoxide (DLco) of at least 30% and less than 80% predicted. Participants fulfilled protocol-defined criteria for ILD progression in the 24 months before screening, despite management considered appropriate in clinical practice for the individual ILD. Participants were randomly assigned 1:1 by means of a pseudo-random number generator to receive nintedanib 150 mg twice daily or placebo for at least 52 weeks. Participants, investigators, and other personnel involved in the trial and analysis were masked to treatment assignment until after database lock. In this subgroup analysis, we assessed the rate of decline in FVC (mL/year) over 52 weeks in patients who received at least one dose of nintedanib or placebo in five prespecified subgroups based on the ILD diagnoses documented by the investigators: hypersensitivity pneumonitis, autoimmune ILDs, idiopathic non-specific interstitial pneumonia, unclassifiable idiopathic interstitial pneumonia, and other ILDs. The trial has been completed and is registered with ClinicalTrials.gov, number NCT02999178. FINDINGS Participants were recruited between Feb 23, 2017, and April 27, 2018. Of 663 participants who received at least one dose of nintedanib or placebo, 173 (26%) had chronic hypersensitivity pneumonitis, 170 (26%) an autoimmune ILD, 125 (19%) idiopathic non-specific interstitial pneumonia, 114 (17%) unclassifiable idiopathic interstitial pneumonia, and 81 (12%) other ILDs. The effect of nintedanib versus placebo on reducing the rate of FVC decline (mL/year) was consistent across the five subgroups by ILD diagnosis in the overall population (hypersensitivity pneumonitis 73·1 [95% CI -8·6 to 154·8]; autoimmune ILDs 104·0 [21·1 to 186·9]; idiopathic non-specific interstitial pneumonia 141·6 [46·0 to 237·2]; unclassifiable idiopathic interstitial pneumonia 68·3 [-31·4 to 168·1]; and other ILDs 197·1 [77·6 to 316·7]; p=0·41 for treatment by subgroup by time interaction). Adverse events reported in the subgroups were consistent with those reported in the overall population. INTERPRETATION The INBUILD trial was not designed or powered to provide evidence for a benefit of nintedanib in specific diagnostic subgroups. However, its results suggest that nintedanib reduces the rate of ILD progression, as measured by FVC decline, in patients who have a chronic fibrosing ILD and progressive phenotype, irrespective of the underlying ILD diagnosis. FUNDING Boehringer Ingelheim.
Collapse
Affiliation(s)
- Athol U Wells
- National Institute for Health Research Respiratory Biomedical Research Unit, Royal Brompton and Harefield NHS Foundation Trust, London, UK
| | - Kevin R Flaherty
- Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI, USA
| | - Kevin K Brown
- Department of Medicine, National Jewish Health, Denver, CO, USA
| | - Yoshikazu Inoue
- Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai City, Osaka, Japan
| | - Anand Devaraj
- Department of Radiology, Royal Brompton and Harefield NHS Foundation Trust, London, UK; National Heart and Lung Institute, Imperial College, London, UK
| | - Luca Richeldi
- Fondazione Policlinico A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy
| | - Teng Moua
- Division of Pulmonary and Critical Care Medicine, Mayo Clinic Rochester, Rochester, MN, USA
| | - Bruno Crestani
- Université de Paris, Inserm U1152, APHP, Hôpital Bichat, Centre de reference constitutif pour les maladies pulmonaires rares, Paris, France
| | - Wim A Wuyts
- Unit for Interstitial Lung Diseases, Department of Pulmonary Medicine, University Hospitals Leuven, Leuven, Belgium
| | | | - Manuel Quaresma
- Boehringer Ingelheim International, Ingelheim am Rhein, Germany
| | | | | | - Martin Kolb
- McMaster University and St Joseph's Healthcare, Hamilton, Ontario, Canada
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Ogawa H, Sakai Y, Nishio W, Fujibayashi Y, Nishikubo M, Nishioka Y, Tane S, Kitamura Y, Sudo T, Sakuma Y, Yoshimura M. P1.12-23 DLL3 Is a Predictive Marker of Sensitivity to Adjuvant Chemotherapy for High-Grade Neuroendocrine Tumors. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1136] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
7
|
Okuma H, Tane S, Nishioka Y, Ogawa H, Kitamura Y, Nishio W, Yoshimura M. P2.17-15 Clinical Features and Prognosis of Lung Cancer with Cavity Lesion. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1926] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
8
|
Allard MA, Nishioka Y, Beghdadi N, Imai K, Gelli M, Yamashita S, Kitano Y, Kokudo T, Yamashita YI, Sa Cunha A, Vibert E, Elias D, Cherqui D, Goere D, Adam R, Baba H, Hasegawa K. Multicentre study of perioperative versus adjuvant chemotherapy for resectable colorectal liver metastases. BJS Open 2019; 3:678-686. [PMID: 31592094 PMCID: PMC6773651 DOI: 10.1002/bjs5.50174] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2018] [Accepted: 03/20/2019] [Indexed: 01/17/2023] Open
Abstract
Background It is not known whether perioperative chemotherapy, compared with adjuvant chemotherapy alone, improves disease‐free survival (DFS) in patients with upfront resectable colorectal liver metastases (CLM). The aim of this study was to estimate the impact of neoadjuvant 5‐fluorouracil, leucovorin and oxaliplatin (FOLFOX) on DFS in patients with upfront resectable CLM. Methods Consecutive patients who presented with up to five resectable CLM at two Japanese and two French centres in 2008–2015 were included in the study. Both French institutions favoured perioperative FOLFOX, whereas the two Japanese groups systematically preferred upfront surgery plus adjuvant chemotherapy. Inverse probability of treatment weighting (IPTW) and Cox regression multivariable models were used to adjust for confounding. The primary outcome was DFS. Results Some 300 patients were included: 151 received perioperative chemotherapy and 149 had upfront surgery plus adjuvant chemotherapy. The weighted 3‐year DFS rate was 33·5 per cent after perioperative chemotherapy compared with 27·1 per cent after upfront surgery plus adjuvant chemotherapy (hazard ratio (HR) 0·85, 95 per cent c.i. 0·62 to 1·16; P = 0·318). For the subgroup of 165 patients who received adjuvant FOLFOX successfully (for at least 3 months), the adjusted effect of neoadjuvant chemotherapy was not significant (HR 1·19, 0·74 to 1·90; P = 0·476). No significant effect of neoadjuvant chemotherapy was observed in multivariable regression analysis. Conclusion Compared with adjuvant chemotherapy, perioperative FOLFOX does not improve DFS in patients with resectable CLM, provided adjuvant chemotherapy is given successfully.
Collapse
Affiliation(s)
- M-A Allard
- Centre Hépatobiliaire Paul Brousse Hospital, Université Paris Sud Villejuif France
| | - Y Nishioka
- Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine University of Tokyo Tokyo Japan
| | - N Beghdadi
- Centre Hépatobiliaire Paul Brousse Hospital, Université Paris Sud Villejuif France
| | - K Imai
- Department of Gastroenterological Surgery, Graduate School of Medical Sciences Kumamoto University Kumamoto Japan
| | - M Gelli
- Department of Oncological Surgery Gustave Roussy Villejuif France
| | - S Yamashita
- Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine University of Tokyo Tokyo Japan
| | - Y Kitano
- Department of Gastroenterological Surgery, Graduate School of Medical Sciences Kumamoto University Kumamoto Japan
| | - T Kokudo
- Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine University of Tokyo Tokyo Japan
| | - Y-I Yamashita
- Department of Gastroenterological Surgery, Graduate School of Medical Sciences Kumamoto University Kumamoto Japan
| | - A Sa Cunha
- Centre Hépatobiliaire Paul Brousse Hospital, Université Paris Sud Villejuif France
| | - E Vibert
- Centre Hépatobiliaire Paul Brousse Hospital, Université Paris Sud Villejuif France
| | - D Elias
- Department of Oncological Surgery Gustave Roussy Villejuif France
| | - D Cherqui
- Centre Hépatobiliaire Paul Brousse Hospital, Université Paris Sud Villejuif France
| | - D Goere
- Department of Oncological Surgery Gustave Roussy Villejuif France
| | - R Adam
- Centre Hépatobiliaire Paul Brousse Hospital, Université Paris Sud Villejuif France
| | - H Baba
- Department of Gastroenterological Surgery, Graduate School of Medical Sciences Kumamoto University Kumamoto Japan
| | - K Hasegawa
- Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine University of Tokyo Tokyo Japan
| |
Collapse
|
9
|
Israel-Biet D, Maher T, Stowasser S, Nishioka Y, White E, Cottin V, Noth I, Selman M, Wachtlin D, Diefenbach C, Jenkins R. Étude de l’effet du nintédanib sur les variations des biomarqueurs du renouvellement de la MEC chez les patients présentant une FPI et un déclin limité de la CVF : plan de l’étude INMARK. Rev Mal Respir 2019. [DOI: 10.1016/j.rmr.2018.10.290] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
10
|
Ogawa H, Tanaka Y, Kitamura Y, Tanaka H, Nishioka Y, Tane S, Nishio W, Maniwa Y, Yoshimura M. P1.12-05 Efficacy of Perioperative Chemotherapy for High-Grade Neuroendocrine Tumors. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.840] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
11
|
Nishioka Y, Hasegawa K, Saiura A, Oba M, Yamamoto J, Nomura Y, Takayama T, Hashiguchi Y, Shibasaki M, Sakamoto H, Yamagata S, Aoyanagi N, Kaneko H, Koyama H, Miyagawa S, Mise Y, Shinozaki E, Yoshida S, Nozawa H, Kokudo N. A multicenter phase II trial to evaluate the efficacy of mFOLFOX6+cetuximab as induction chemotherapy to achieve R0 surgical resection for advanced colorectal liver metastases (NEXTO trial). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy281.039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
12
|
Ishiba T, Danenberg K, Usher J, Nakagawa T, Oda G, Uetake H, Hoshino N, Nishioka Y, Kawano T. Frequencies and expression levels of programmed death ligand 1 (PD-L1) in circulating tumor RNA (ctRNA) in various cancer types. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx653.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
13
|
Sano F, Mizuuchi T, Nagasaki K, Okada H, Kobayashi S, Kondo K, Hanatani K, Nakamura Y, Nakasuga M, Besshou S, Yamamoto S, Yokoyama M, Suzuki Y, Manabe Y, Shidara H, Takamiya T, Ohno Y, Nishioka Y, Yukimoto H, Takahashi K, Fukagawa Y, Kawazome H, Kaneko M, Tsuboi S, Nakazawa S, Nishio S, Yamada M, Ijiri Y, Senju T, Yaguchi K, Sakamoto K, Tohshi K, Shibano M, Tribaldos V, Tabares F, Obiki T. Observation of H-Mode Operation Windows for ECH Plasmas in Heliotron J. Fusion Science and Technology 2017. [DOI: 10.13182/fst04-a567] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- F. Sano
- Kyoto University, Institute of Advanced Energy, Gokasho, Uji, Japan
| | - T. Mizuuchi
- Kyoto University, Institute of Advanced Energy, Gokasho, Uji, Japan
| | - K. Nagasaki
- Kyoto University, Institute of Advanced Energy, Gokasho, Uji, Japan
| | - H. Okada
- Kyoto University, Institute of Advanced Energy, Gokasho, Uji, Japan
| | - S. Kobayashi
- Kyoto University, Institute of Advanced Energy, Gokasho, Uji, Japan
| | - K. Kondo
- Kyoto University, Graduate School of Energy Science, Yoshidahonmachi, Kyoto, Japan
| | - K. Hanatani
- Kyoto University, Institute of Advanced Energy, Gokasho, Uji, Japan
| | - Y. Nakamura
- Kyoto University, Institute of Advanced Energy, Gokasho, Uji, Japan
| | - M. Nakasuga
- Kyoto University, Institute of Advanced Energy, Gokasho, Uji, Japan
| | - S. Besshou
- Kyoto University, Graduate School of Energy Science, Yoshidahonmachi, Kyoto, Japan
| | - S. Yamamoto
- Kyoto University, Graduate School of Energy Science, Yoshidahonmachi, Kyoto, Japan
| | - M. Yokoyama
- National Institute for Fusion Science, Gifu, Toki, Japan
| | - Y. Suzuki
- Kyoto University, Graduate School of Energy Science, Yoshidahonmachi, Kyoto, Japan
| | - Y. Manabe
- Kyoto University, Graduate School of Energy Science, Yoshidahonmachi, Kyoto, Japan
| | - H. Shidara
- Kyoto University, Graduate School of Energy Science, Yoshidahonmachi, Kyoto, Japan
| | - T. Takamiya
- Kyoto University, Graduate School of Energy Science, Yoshidahonmachi, Kyoto, Japan
| | - Y. Ohno
- Kyoto University, Graduate School of Energy Science, Yoshidahonmachi, Kyoto, Japan
| | - Y. Nishioka
- Kyoto University, Graduate School of Energy Science, Yoshidahonmachi, Kyoto, Japan
| | - H. Yukimoto
- Kyoto University, Graduate School of Energy Science, Yoshidahonmachi, Kyoto, Japan
| | - K. Takahashi
- Kyoto University, Graduate School of Energy Science, Yoshidahonmachi, Kyoto, Japan
| | - Y. Fukagawa
- Kyoto University, Graduate School of Energy Science, Yoshidahonmachi, Kyoto, Japan
| | - H. Kawazome
- Kyoto University, Graduate School of Energy Science, Yoshidahonmachi, Kyoto, Japan
| | - M. Kaneko
- Kyoto University, Graduate School of Energy Science, Yoshidahonmachi, Kyoto, Japan
| | - S. Tsuboi
- Kyoto University, Graduate School of Energy Science, Yoshidahonmachi, Kyoto, Japan
| | - S. Nakazawa
- Kyoto University, Institute of Advanced Energy, Gokasho, Uji, Japan
| | - S. Nishio
- Kyoto University, Graduate School of Energy Science, Yoshidahonmachi, Kyoto, Japan
| | - M. Yamada
- Kyoto University, Graduate School of Energy Science, Yoshidahonmachi, Kyoto, Japan
| | - Y. Ijiri
- Kyoto University, Institute of Advanced Energy, Gokasho, Uji, Japan
| | - T. Senju
- Kyoto University, Institute of Advanced Energy, Gokasho, Uji, Japan
| | - K. Yaguchi
- Kyoto University, Institute of Advanced Energy, Gokasho, Uji, Japan
| | - K. Sakamoto
- Kyoto University, Institute of Advanced Energy, Gokasho, Uji, Japan
| | - K. Tohshi
- Kyoto University, Institute of Advanced Energy, Gokasho, Uji, Japan
| | - M. Shibano
- Kyoto University, Institute of Advanced Energy, Gokasho, Uji, Japan
| | - V. Tribaldos
- Laboratorio Nacional de Fusion, Asociacion EURATOMCIEMAT, Madrid, Spain
| | - F. Tabares
- Laboratorio Nacional de Fusion, Asociacion EURATOMCIEMAT, Madrid, Spain
| | - T. Obiki
- Kyushu Institute of Information Sciences, Dazaifu, Fukuoka, Japan
| |
Collapse
|
14
|
Tajima H, Nishioka Y, Sato S, Suzuki T, Kimata M. Magnetic field effects of photocarrier generation in bulk heterojunctions at low temperature. Dalton Trans 2016; 45:16616-16623. [PMID: 27484333 DOI: 10.1039/c6dt02132h] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
We report an experimental investigation of the magnetic field effect (MFE) in polymer bulk heterojunction devices at temperatures below 10 K using photocarrier extraction by linearly increasing voltages. The examined devices were composed of an active layer of poly(3-hexylthiophene) and [6,6]-phenyl-C61-butyric acid methyl ester. In the experiments, the delay time (td) dependence of the MFE was investigated in detail. For td < 80 μs, a positive MFE was observed in the field region B < 0.1 T and a negative MFE was observed for B > 0.2 T. For td > 8 ms, only a positive MFE proportional to B2 was observed. For the photocurrent pulse detected immediately after light irradiation, the MFE was negligibly small. In a high magnetic field of 15 T, a significant MFE exceeding 80% was observed at 1.8 K for td = 800 ms. We discuss the results based on a model of triplet-singlet (or singlet-triplet) conversion in the magnetic field and estimate the exchange integral for the charge-transfer exciton in this photovoltaic cell.
Collapse
Affiliation(s)
- H Tajima
- Graduate School of Material Science, University of Hyogo, 3-2-1 Kohto, Kamigori-cho, Ako-gun, Hyogo 678-1297, Japan.
| | | | | | | | | |
Collapse
|
15
|
Matsumoto S, Yoh K, Kodani M, Ohashi K, Saeki S, Furuya N, Nishioka Y, Ohe Y, Seto T, Hayashi R, Kataoka Y, Fukui T, Sakamoto T, Ikemura S, Kohno T, Tsuta K, Tsuchihara K, Goto K. Detectability of druggable gene fusions by amplicon-based next generation sequencing in nationwide lung cancer genomic screening project (LC-SCRUM-Japan). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw383.14] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
16
|
Hasegawa K, Tagawa M, Takagi K, Tsukamoto H, Tomioka Y, Suzuki T, Nishioka Y, Ohrui T, Numasaki M. Anti-tumor immunity elicited by direct intratumoral administration of a recombinant adenovirus expressing either IL-28A/IFN-λ2 or IL-29/IFN-λ1. Cancer Gene Ther 2016; 23:266-77. [PMID: 27561689 DOI: 10.1038/cgt.2016.29] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/25/2015] [Revised: 05/11/2016] [Accepted: 05/12/2016] [Indexed: 12/14/2022]
Abstract
Interleukin (IL)-28A/interferon (IFN)-λ2 and IL-29/IFN-λ1 have been demonstrated to elicit direct and indirect anti-tumor actions. In this study, we constructed an adenovirus vector expressing either IL-28A/IFN-λ2 (AdIL-28A) or IL-29/IFN-λ1 (AdIL-29) to evaluate the therapeutic properties of intratumoral injection of recombinant adenovirus to apply for the clinical implementation of cancer gene therapy. Despite the lack of an anti-proliferative effect on MCA205 and B16-F10 cells, a retarded growth of established subcutaneous tumors was observed following multiple injections of either AdIL-28A or AdIL-29 when compared with AdNull. In vivo cell depletion experiments displayed that both NK cells and CD8(+) T cells have a major role in AdIL-28A-mediated tumor growth suppression. A significant increase in the number of infiltrating CD8(+) T cells into the tumors treated with either AdIL-28A or AdIL-29 was observed. Moreover, specific anti-tumor cytotoxic T lymphocyte reactivity was detected in spleen cells from animals treated with either AdIL-28A or AdIL-29. In IFN-γ-deficient mice, anti-tumor activities of AdIL-28A were completely impaired, indicating that IFN-γ is critically involved in the tumor growth inhibition triggered by AdIL-28A. IL-12 provided a synergistic anti-tumor effect when combined with AdIL-28A. These results indicate that AdIL-28A and AdIL-29 could be successfully utilized as an alternative cancer immunogene therapy.
Collapse
Affiliation(s)
- K Hasegawa
- Laboratory of Clinical Science and Biomedicine, Faculty of Pharmaceutical Sciences, Josai University, Sakado, Japan
| | - M Tagawa
- Division of Pathology and Cell Therapy, Chiba Cancer Center Research Institute, Chiba, Japan
| | - K Takagi
- Departments of Pathology and Histotechnology, Tohoku University Graduate School of Medicine, Sendai, Japan
| | - H Tsukamoto
- Laboratory of Oncology, Pharmacy Practice and Sciences, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan
| | - Y Tomioka
- Laboratory of Oncology, Pharmacy Practice and Sciences, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan
| | - T Suzuki
- Departments of Pathology and Histotechnology, Tohoku University Graduate School of Medicine, Sendai, Japan
| | - Y Nishioka
- Department of Respiratory Medicine and Rheumatology, Institute of Health Biosciences, University of Tokushima Graduate School, Tokushima, Japan
| | - T Ohrui
- Division of Geriatric Pharmacotherapy, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan
| | - M Numasaki
- Laboratory of Clinical Science and Biomedicine, Faculty of Pharmaceutical Sciences, Josai University, Sakado, Japan
| |
Collapse
|
17
|
Sagawa A, Funahashi K, Matsubara T, Izumihara T, Adachi M, Iwahasi M, Oyama T, Nishioka Y, Hashimoto K, Oribe M, Takahashi Y. SAT0575 Ra Patients' Expectations of Treatment - Comparison with the Result of Surveys in Multi-Cohort-. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.2545] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
18
|
Yamanaka H, Seto Y, Nagaoka S, Bae SC, Kasama T, Lee SK, Kobayashi H, Nishioka Y, Tanaka Y, Takeuchi T. THU0169 Discontinuation of Etanercept in Early Rheumatoid Arthritis Patients who Have Achieved Sustained Remission: Results of the Randomized Controlled Trial in Period 2 of the Encourage Study. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.2429] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
19
|
Iwase T, Takao T, Akaike M, Ise T, Yagi S, Yamaguchi K, Yamada H, Nishioka Y, Harada M, Sata M. Differentiation of left ventricular systolic dysfunction related to cardiac sarcoidosis and other heart diseases using contrast-enhanced cardiovascular magnetic resonance. Eur Heart J 2013. [DOI: 10.1093/eurheartj/eht309.p4215] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
20
|
Wakabayashi H, Hasegawa M, Sudo A, Nishioka Y, Nishioka K. AB0533 Tocilizumab improves treatment outcomes in patients with rheumatoid arthritis for whom anti-TNF agents has failed. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2012-eular.533] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
21
|
Murakami K, Azuma M, Hirota K, Ono T, Nishioka Y, Miyake Y. P16 The correlation between antibiotic tolerance and virulence of Pseudomonas aeruginosa clinical isolates. Int J Antimicrob Agents 2013. [DOI: 10.1016/s0924-8579(13)70261-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
22
|
Kunita A, Kaneko M, Abe S, Fukayama M, Nishioka Y, Kato Y. 200 Suppression of Tumor Growth and Metastasis by Anti-Podoplanin Antibodies. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)71998-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
23
|
Nishioka Y, Sakamoto M, Kinukawa N, Sanui H, Inomata H, Nose Y. Recurrence risk factors in patients with the Vogt-Koyanagi-Harada syndrome in Japan. Ocul Immunol Inflamm 2012; 3:73-80. [PMID: 22827273 DOI: 10.3109/09273949509085034] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
The Vogt-Koyanagi-Harada (VKH) syndrome is a form of recurrent uveitis with often a poor long-term visual acuity. The risk factors for recurrence of the VKH syndrome were investigated statistically by using a multiple logistic regression model. The clinical data of 87 patients were used for the statistical analysis. Among them, 58 patients (66.8%) had no recurrences, while 29 patients (33.3%) had recurrences. By multiple logistic regression analysis, dysacousia (p<0.01), cutaneous manifestations (p<0. 05), prodromal symptoms (p<0. 05), onset to treatment interval (days) (p<0. 05) and retinal detachment (p<0. 01) were significantly and independently associated with the recurrence. The Relapse Score was constructed by using a logistic model as follows: Relapse Score=+1. 459X (Dysacousia) + 1. 458x (Cutaneous manifestations) +0. 032x (Onset to treatment interval) -1. 637x (Prodromal symptoms) -1. 773x (Retinal detachment)+1. 247. It is supposed that the Relapse Score might be helpful for predicting the clinical course and modifying the dose or duration of systemic steroid therapy of the patients with the VKH syndrome.
Collapse
Affiliation(s)
- Y Nishioka
- Department of Medical Informatics, Japan
| | | | | | | | | | | |
Collapse
|
24
|
Ogawa H, Azuma M, Uehara H, Takahashi T, Nishioka Y, Sone S, Izumi K. Nerve growth factor derived from bronchial epithelium after chronic mite antigen exposure contributes to airway hyperresponsiveness by inducing hyperinnervation, and is inhibited by in vivo siRNA. Clin Exp Allergy 2011; 42:460-70. [PMID: 22168511 DOI: 10.1111/j.1365-2222.2011.03918.x] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2011] [Revised: 10/11/2011] [Accepted: 10/17/2011] [Indexed: 12/12/2022]
Abstract
BACKGROUND Bronchial asthma is a chronic allergic airway inflammatory disease. Neurotrophins, including nerve growth factor (NGF), play an important role in the pathogenesis of asthma. However, the effects of NGF derived from epithelium on airway hyperresponsiveness (AHR) after antigen sensitization/exposure remain uncertain. OBJECTIVE In this study, we examined the role of NGF on AHR after chronic antigen exposure and the effect of inhibiting NGF by in vivo siRNA on AHR exacerbation. METHODS We generated chronic mouse models of bronchial asthma using house-dust mite antigen (Dermatophagoides pteronyssinus; Dp). NGF concentrations in bronchoalveolar lavage fluid (BALF), lung histopathology, hyperresponsiveness, and related neuronal peptides and cytokines in supernatants of lung homogenates were determined. RESULTS NGF in BALF was increased in a dose- and time-dependent manner, and was expressed primarily in bronchial epithelium. Nerve fibres and substance P-positive fibres were detected in subepithelium of Dp-sensitized and challenged mice over 4 weeks of mite antigen exposure. AHR was positively correlated with NGF concentration and nerve fibre innervation. AHR, modulation of innervation, and increased substance P were inhibited by in vivo administration of siRNA that targeted NGF, although the inhibition of NGF did not affect allergic inflammation and subepithelial fibrosis. CONCLUSION AND CLINICAL RELEVANCE These findings suggest that NGF derived from bronchial and alveolar epithelium plays an important role in AHR after chronic exposure to mite antigen. NGF inhibition could potentially manage bronchial asthma, including AHR.
Collapse
Affiliation(s)
- H Ogawa
- Department of Molecular and Environmental Pathology, Institute of Health Biosciences, University of Tokushima Graduate School, Tokushima, Japan.
| | | | | | | | | | | | | |
Collapse
|
25
|
Ogawa H, Azuma M, Muto S, Nishioka Y, Honjo A, Tezuka T, Uehara H, Izumi K, Itai A, Sone S. IκB kinase β inhibitor IMD-0354 suppresses airway remodelling in a Dermatophagoides pteronyssinus-sensitized mouse model of chronic asthma. Clin Exp Allergy 2011; 41:104-15. [PMID: 20573155 DOI: 10.1111/j.1365-2222.2010.03564.x] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
BACKGROUND Nuclear factor (NF)-κB is a transcription factor that regulates cytokine and chemokine production in various inflammatory diseases, including bronchial asthma. IκB kinase (IKK) β is important for NF-κB activation in inflammatory conditions, and is possibly related to airway remodelling. Thus, inhibition of the IKKβ-NF-κB pathway may be an ideal strategy for the management of airway remodelling. OBJECTIVE We examined the effects of a newly synthesized IKKβ inhibitor, IMD-0354, in a chronic allergen exposure model of bronchial asthma in mice. METHODS A chronic mouse model was generated by challenge with house dust mite antigen (Dermatophagoides pteronyssinus). IMD-0354 was administrated intraperitoneally in therapeutic groups. Lung histopathology, hyperresponsiveness and the concentrations of mediators and molecules in supernatants of lung homogenates were determined. RESULTS NF-κB activation was inhibited by prolonged periods of IMD-0354 administration. IMD-0354 reduced the numbers of bronchial eosinophils. IMD-0354 also inhibited the pathological features of airway remodelling, including goblet cell hyperplasia, subepithelial fibrosis, collagen deposition and smooth muscle hypertrophy. Inhibition of these structural changes by IMD-0354 was the result of the suppressing the production and activation of remodelling-related mediators, such as TGF-β, via inhibition of IKKβ. IMD-0354 inhibited IL-13 and IL-1β production, and it restored the production of IFN-γ. It also ameliorated airway hyperresponsiveness. CONCLUSION IKKβ plays crucial roles in airway inflammation and remodelling in a chronic mouse model of asthma. A specific IKKβ inhibitor, IMD-0354, may be therapeutically beneficial for treating airway inflammation and remodelling in chronic asthma.
Collapse
Affiliation(s)
- H Ogawa
- Department of Respiratory Medicine & Rheumatology Department of Molecular and Environmental Pathology, Institute of Health Biosciences, University of Tokushima Graduate School, Tokushima, Japan.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Nishioka Y, Abe S, Kishuku M, Hanibuchi M, Kakiuchi S, Kawazoe K, Minakuchi K, Kaneko M, Kato Y. PP 95 Targeted therapy for mesothelioma using anti-podoplanin antibody NZ-1 via ADCC. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)72686-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/15/2022]
|
27
|
Wakabayashi H, Oka H, Nishioka Y, Hasegawa M, Sudo A, Nishioka K. Do biologics-naïve patients with rheumatoid arthritis respond better to tocilizumab than patients for whom anti-TNF agents have failed? A retrospective study. Clin Exp Rheumatol 2011; 29:314-317. [PMID: 21418781] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2010] [Accepted: 12/15/2010] [Indexed: 05/30/2023]
Abstract
OBJECTIVES To determine responses to tocilizumab between patients with rheumatoid arthritis (RA) who switched to anti-TNF agents and those who are biologics-naïve. METHODS This retrospective study investigated 107 patients with RA who were treated with tocilizumab. At baseline, 61 of them had already been treated with anti-TNF agents (switched group; 46 for inefficacy and 15 for adverse events), and 46 were biologics-naïve (naïve group). Treatment responses to tocilizumab at week 12 and 24 were compared between the switched and naïve groups using the disease activity score 28 (DAS28). RESULTS Forty-two (91.3%) and 50 (82.0%) patients in the naïve and switched groups, respectively, completed 24 weeks of tocilizumab treatment. The DAS28-ESR and DAS28-CRP values (means±SD) at weeks 12 and 24 compared to baseline decreased significantly for the naïve and switched groups. The DAS28-ESR and DAS28-CRP values at weeks 12 and 24 were significantly decreased in the naïve group, compared to the switched group. Disease activity was improved in the naïve patients compared to the switched patients. CONCLUSIONS Tocilizumab was safe, tolerable, and clinically effective for patients with inadequate responses to anti-TNF therapy and for those who were biologics-naïve, and it was more effective among the latter.
Collapse
Affiliation(s)
- H Wakabayashi
- Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu, Japan.
| | | | | | | | | | | |
Collapse
|
28
|
Kishi J, Nishioka Y, Kuwahara T, Kakiuchi S, Azuma M, Aono Y, Makino H, Kinoshita K, Kishi M, Batmunkh R, Uehara H, Izumi K, Sone S. Blockade of Th1 chemokine receptors ameliorates pulmonary granulomatosis in mice. Eur Respir J 2011; 38:415-24. [PMID: 21273392 DOI: 10.1183/09031936.00070610] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Sarcoidosis is a granulomatous disease of unknown aetiology. We identified immunological targets for the treatment of pulmonary granulomatosis using a murine model generated with Propionibacterium acnes. Sensitisation and challenge using heat-killed P. acnes and dendritic cells (DCs) were performed to produce pulmonary granulomatosis in C57BL/6 mice. Immunological analyses using ELISA as well as cDNA microarray analysis were used to search for cytokines or chemokines associated with the formation of granulomas in the lungs. Co-administration of P. acnes and DCs reproducibly induced the formation of pulmonary granulomas, which resembled sarcoid granulomas. The cDNA microarray assay demonstrated that the gene expression of CXCL9 and CXCL10, ligands for CXCR3, and of CCL4, a ligand for CCR5, was strongly upregulated during granulomatosis. ELISA confirmed that levels of CXCL9 and CXCL10 as well as T-helper (Th)1 cytokines and chemokines including tumour necrosis factor-α and interferon-γ were elevated in bronchoalveolar lavage fluid (BALF). The blockade of Th1 chemokine receptors using TAK-779, a dual blocker for CXCR3 and CCR5, led to reduced numbers of CXCR3+CD4+ and CCR5+CD4+ T-cells in BALF. Furthermore, administration of TAK-779 ameliorated the granulomatosis. The targeted inhibition of Th1 chemokines might be useful for inhibiting Th1-biased granulomatous diseases, including sarcoidosis.
Collapse
Affiliation(s)
- J Kishi
- Department of Respiratory Medicine and Rheumatology, University of Tokushima Graduate School, 3-18-15 Kuramoto-cho, Tokushima 770-8503, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Tanaka Y, Ohishi K, Yonekawa T, Yodoya N, Iwamoto S, Nishioka Y, Tatara Y, Matsumoto T, Masuya M. Effect of washing solution on platelet counts following transfusion with twice-washed platelets: a single-patient experience. Transfus Med 2010; 20:358-60. [DOI: 10.1111/j.1365-3148.2010.01010.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
30
|
Yano S, Wang W, Li Q, Yamada T, Matsumoto K, Mitsudomi T, Yatabe Y, Hanibuchi M, Nishioka Y, Sone S. Hepatocyte growth factor as inducer of gefitinib resistance in non-small cell lung cancer harboring EGFR activating mutations. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e19034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e19034 Background: Non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations (EGFRmu) responds favorably to the EGFR tyrosine kinase inhibitors (EGFR-TKIs), gefitinib or erlotinib. However, 25–30% of patients with EGFRmu show intrinsic resistance, and the responders invariably acquire resistance to EGFR-TKIs. Here, we examined the role of hepatocyte growth factor (HGF), a specific ligand of MET, in gefitinib resistance of NSCLC with EGFRmu. Methods: NSCLC cells, PC-9 and HCC827, with EGFRmu, but not T790M second mutation in EGFR or MET amplification, were used in this study. Sensitivity to gefitinib was determined by MTT assay. Phosphorylation of MET, EGFR, ERBB3, and the PI3K/Akt pathway were examined by Western blotting. HGF expression in 20 tumors from 16 NSCLC patients with EGFRmu who were treated with gefitinib was determined by immunohistochemistry. Results: HGF induced resistance to gefitinib by restoring Akt phosphorylation independently of ErbB3. Specific down-regulation of MET, but not ErbB3, reversed gefitinib resistance and Akt phosphorylation induced by HGF. Importantly, high levels of immunoreactivity for HGF were detected in cancer cells of 3 of 3 intrinsic resistant tumors and in one of 2 tumors with acquired resistance without T790M second mutation or MET amplification. Conclusions: The findings indicate that HGF-mediated MET activation is a novel mechanism of intrinsic and acquired gefitinib-resistance in NSCLC with EGFRmu. Therefore, inhibition of HGF-MET signaling may be considerable strategy for more successful treatment with EGFR-TKIs. [Table: see text]
Collapse
Affiliation(s)
- S. Yano
- Kanazawa University Cancer Research Institute, Kanazawa, Ishikawa, Japan; Aichi Cancer Center, Nagoya, Japan; University of Tokushima Graduate School, Tokushima, Japan
| | - W. Wang
- Kanazawa University Cancer Research Institute, Kanazawa, Ishikawa, Japan; Aichi Cancer Center, Nagoya, Japan; University of Tokushima Graduate School, Tokushima, Japan
| | - Q. Li
- Kanazawa University Cancer Research Institute, Kanazawa, Ishikawa, Japan; Aichi Cancer Center, Nagoya, Japan; University of Tokushima Graduate School, Tokushima, Japan
| | - T. Yamada
- Kanazawa University Cancer Research Institute, Kanazawa, Ishikawa, Japan; Aichi Cancer Center, Nagoya, Japan; University of Tokushima Graduate School, Tokushima, Japan
| | - K. Matsumoto
- Kanazawa University Cancer Research Institute, Kanazawa, Ishikawa, Japan; Aichi Cancer Center, Nagoya, Japan; University of Tokushima Graduate School, Tokushima, Japan
| | - T. Mitsudomi
- Kanazawa University Cancer Research Institute, Kanazawa, Ishikawa, Japan; Aichi Cancer Center, Nagoya, Japan; University of Tokushima Graduate School, Tokushima, Japan
| | - Y. Yatabe
- Kanazawa University Cancer Research Institute, Kanazawa, Ishikawa, Japan; Aichi Cancer Center, Nagoya, Japan; University of Tokushima Graduate School, Tokushima, Japan
| | - M. Hanibuchi
- Kanazawa University Cancer Research Institute, Kanazawa, Ishikawa, Japan; Aichi Cancer Center, Nagoya, Japan; University of Tokushima Graduate School, Tokushima, Japan
| | - Y. Nishioka
- Kanazawa University Cancer Research Institute, Kanazawa, Ishikawa, Japan; Aichi Cancer Center, Nagoya, Japan; University of Tokushima Graduate School, Tokushima, Japan
| | - S. Sone
- Kanazawa University Cancer Research Institute, Kanazawa, Ishikawa, Japan; Aichi Cancer Center, Nagoya, Japan; University of Tokushima Graduate School, Tokushima, Japan
| |
Collapse
|
31
|
Hanibuchi M, Ogino H, Ikuta K, Kakiuchi S, Uehara H, Tsuruoka A, Uenaka T, Nishioka Y, Yano S, Sone S. 165 POSTER Novel therapeutic efficacy of E7080 for controlling experimental metastases of human lung cancer cells in natural killer cell-depleted severe combined immunodeficient mice. EJC Suppl 2008. [DOI: 10.1016/s1359-6349(08)72097-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
|
32
|
Matsumoto A, Matsukawa Y, Nishioka Y, Harada M, Horikiri Y, Yamahara H. A new method of preparing TRH derivative-loaded poly(dl-lactide-coglycolide) microspheres based on a solid solution system. Drug Discov Ther 2008; 2:45-51. [PMID: 22504454] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
We investigated a new method of preparing peptide-loaded poly(dl-lactide-co-glycolide) microspheres with high encapsulation efficiency, low initial burst, and long-term sustained release by dissolving a peptide in a polymer by applying a solid solution system to the preparation of an oil phase. Solid solutions were prepared by dissolving a polymer (poly(dl-lactide-co-glycolide)) and a peptide (TRH derivative) in mixed solvents and then evaporating the solvents. Microspheres were prepared by an O/W emulsion solvent evaporation method, using the solution of the solid solution in dichloromethane as an oil phase. The state of the peptide in the solid solution and in the microspheres was evaluated by X-ray diffraction analysis. Release of the peptide from the microspheres was evaluated by an in vitro drug release test. Observation of the oil phase, X-ray diffraction analysis, and DSC analysis revealed that the peptides were dispersed in a molecular state in the solid solution and in microspheres with peptide loading of up to 15%. Encapsulation efficiency was over 90% for microspheres with peptide loading of up to 15%. The release of the peptide from the microspheres lasted over 21 days at least with the limited initial burst in vitro. High encapsulation efficiency, low initial burst, and long-term sustained release can be accomplished with microspheres prepared by a method based on a solid solution system.
Collapse
|
33
|
Nishioka Y, Manabe K, Kishi J, Wang W, Inayama M, Azuma M, Sone S. CXCL9 and 11 in patients with pulmonary sarcoidosis: a role of alveolar macrophages. Clin Exp Immunol 2007; 149:317-26. [PMID: 17550373 PMCID: PMC1941950 DOI: 10.1111/j.1365-2249.2007.03423.x] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
Abstract
Interferon-inducible protein-10 (IP-10)/CXCL10, which is a ligand for CXC chemokine receptor 3 (CXCR3), is known to be involved in the pathogenesis of pulmonary sarcoidosis. However, the roles of monokine induced by interferon gamma (Mig)/CXCL9 and interferon-inducible T cell alpha chemoattractant (I-TAC)/CXCL11, which are also CXCR3 ligands, remain unclear. Mig/CXCL9, IP-10/CXCL10 and I-TAC/CXCL11 in both bronchoalveolar lavage fluid (BALF) and serum in patients with pulmonary sarcoidosis were measured by enzyme-linked immunosorbent assay (ELISA). The expression of these chemokines in alveolar macrophages was examined using ELISA, quantitative real-time polymerase chain reaction and immunostaining. In BALF, Mig/CXCL9 and IP-10/CXCL10 were significantly elevated in stage II sarcoidosis as compared with the levels in healthy volunteers. In serum, Mig/CXCL9 and I-TAC/CXCL11 were increased in stage II of the disease. The levels of all CXCR3 ligands in BALF were correlated with the numbers of both total and CD4(+) lymphocytes. Alveolar macrophages were stained positive for all CXCR3 ligands and produced increased amounts of these chemokines. Positive staining of the three chemokines was also observed in the epithelioid and giant cells in the sarcoid lungs. These findings suggest that Mig/CXCL9 and I-TAC/CXCL11 as well as IP-10/CXCL10 play important roles in the accumulation of Th1 lymphocytes in sarcoid lungs.
Collapse
Affiliation(s)
- Y Nishioka
- Department of Internal Medicine and Molecular Therapeutics, Institute of Health Biosciences, University of Tokushima Graduate School, Tokushima, Japan.
| | | | | | | | | | | | | |
Collapse
|
34
|
Tsuji A, Kobayashi K, Shima Y, Hamada M, Nishioka Y, Morita S, Horimi T. A phase I/II study of 24-hour infusional irinotecan (CPT-11) therapy in metastaic colorectal cancer. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.3673] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- A. Tsuji
- Kochi Municipal Central Hosp, Kochi-shi, Japan; Nagasaki Univ Graduate Sch, Nagasaki, Japan; Kochi Municipal Central Hosp, Kochi, Japan
| | - K. Kobayashi
- Kochi Municipal Central Hosp, Kochi-shi, Japan; Nagasaki Univ Graduate Sch, Nagasaki, Japan; Kochi Municipal Central Hosp, Kochi, Japan
| | - Y. Shima
- Kochi Municipal Central Hosp, Kochi-shi, Japan; Nagasaki Univ Graduate Sch, Nagasaki, Japan; Kochi Municipal Central Hosp, Kochi, Japan
| | - M. Hamada
- Kochi Municipal Central Hosp, Kochi-shi, Japan; Nagasaki Univ Graduate Sch, Nagasaki, Japan; Kochi Municipal Central Hosp, Kochi, Japan
| | - Y. Nishioka
- Kochi Municipal Central Hosp, Kochi-shi, Japan; Nagasaki Univ Graduate Sch, Nagasaki, Japan; Kochi Municipal Central Hosp, Kochi, Japan
| | - S. Morita
- Kochi Municipal Central Hosp, Kochi-shi, Japan; Nagasaki Univ Graduate Sch, Nagasaki, Japan; Kochi Municipal Central Hosp, Kochi, Japan
| | - T. Horimi
- Kochi Municipal Central Hosp, Kochi-shi, Japan; Nagasaki Univ Graduate Sch, Nagasaki, Japan; Kochi Municipal Central Hosp, Kochi, Japan
| |
Collapse
|
35
|
Kondo M, Hiruma M, Nishioka Y, Mayuzumi N, Mochida K, Ikeda S, Ogawa H. A case of chromomycosis caused by Fonsecaea pedrosoi and a review of reported cases of dematiaceous fungal infection in Japan. Mycoses 2005; 48:221-5. [PMID: 15842342 DOI: 10.1111/j.1439-0507.2005.01089.x] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
We report a case of chromomycosis caused by Fonsecaea pedrosoi that developed in the left buttock of a 63-year-old female farmer. About 4 years ago, the patient developed erythema in the left buttock, which gradually spread. At the first consultation, we noted a well-defined, red-brown, infiltrated erythematous plaque (8 x 6 cm). Histopathological examination revealed a granulomatous lesion, containing sclerotic cells, associated with giant cells in the upper dermis. The causative fungus was difficult to identify due to low conidiogenesis, but was eventually identified by slide culture as F. pedrosoi. Excision and skin graft were performed, and no recurrence has been observed after 2 years. In Japan, 212 cases of dematiaceous fungal infection were reported in the period from 1982 to 2001. The causative fungus was F. pedrosoi in the majority of cases (126/212; 66%), followed by Exophiala jeanselmei (36/212; 19%). Similar incidence of dematiaceous fungal infection was reported in male and female patients. The upper limbs were affected most frequently in both male and female patients. Ten cases were associated with visceral lesions.
Collapse
|
36
|
Tsuji A, Morita S, Shima Y, Nishioka Y, Horimi T, Shirasaka T. Phase II study of CDDP + S-1 combination chemotherapy for advanced and recurrent gastric cancer. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.4148] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- A. Tsuji
- Kochi Municipal Central Hospital, Kochi, Japan; Taiho Pharmaceutical Co, Ltd, Tokyo, Japan
| | - S. Morita
- Kochi Municipal Central Hospital, Kochi, Japan; Taiho Pharmaceutical Co, Ltd, Tokyo, Japan
| | - Y. Shima
- Kochi Municipal Central Hospital, Kochi, Japan; Taiho Pharmaceutical Co, Ltd, Tokyo, Japan
| | - Y. Nishioka
- Kochi Municipal Central Hospital, Kochi, Japan; Taiho Pharmaceutical Co, Ltd, Tokyo, Japan
| | - T. Horimi
- Kochi Municipal Central Hospital, Kochi, Japan; Taiho Pharmaceutical Co, Ltd, Tokyo, Japan
| | - T. Shirasaka
- Kochi Municipal Central Hospital, Kochi, Japan; Taiho Pharmaceutical Co, Ltd, Tokyo, Japan
| |
Collapse
|
37
|
Yamada Y, Yamamoto N, Shimoyama T, Horiike A, Fujisaka Y, Takayama K, Sakamoto T, Nishioka Y, Yasuda S, Tamura T. A phase I pharmacokinetic and pharmacogenomic study of E7070 administered once every 21 days. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.2030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Y. Yamada
- National Cancer Center Hospital, Tokyo, Japan; Clinical Research Center, Eisai Co, Ltd, Tokyo, Japan
| | - N. Yamamoto
- National Cancer Center Hospital, Tokyo, Japan; Clinical Research Center, Eisai Co, Ltd, Tokyo, Japan
| | - T. Shimoyama
- National Cancer Center Hospital, Tokyo, Japan; Clinical Research Center, Eisai Co, Ltd, Tokyo, Japan
| | - A. Horiike
- National Cancer Center Hospital, Tokyo, Japan; Clinical Research Center, Eisai Co, Ltd, Tokyo, Japan
| | - Y. Fujisaka
- National Cancer Center Hospital, Tokyo, Japan; Clinical Research Center, Eisai Co, Ltd, Tokyo, Japan
| | - K. Takayama
- National Cancer Center Hospital, Tokyo, Japan; Clinical Research Center, Eisai Co, Ltd, Tokyo, Japan
| | - T. Sakamoto
- National Cancer Center Hospital, Tokyo, Japan; Clinical Research Center, Eisai Co, Ltd, Tokyo, Japan
| | - Y. Nishioka
- National Cancer Center Hospital, Tokyo, Japan; Clinical Research Center, Eisai Co, Ltd, Tokyo, Japan
| | - S. Yasuda
- National Cancer Center Hospital, Tokyo, Japan; Clinical Research Center, Eisai Co, Ltd, Tokyo, Japan
| | - T. Tamura
- National Cancer Center Hospital, Tokyo, Japan; Clinical Research Center, Eisai Co, Ltd, Tokyo, Japan
| |
Collapse
|
38
|
Kawazome H, Tsuboi S, Kondo K, Mizuuchi T, Sano F, Nagasaki K, Okada H, Kobayashi S, Takahashi K, Shidara H, Manabe Y, Kaneko M, Ohno Y, Takamiya T, Nishioka Y, Yukimoto H, Nakazawa S, Nishio S, Fukagawa Y, Yamada M, Obiki T. Spectroscopic Study of Impurity Behavior in Heliotron-J Plasmas. Fusion Science and Technology 2004. [DOI: 10.13182/fst04-a549] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- Hayato Kawazome
- Kyoto University Graduate School of Energy Science, Gokasho, Uji 611-0011, Japan
| | - Shintaro Tsuboi
- Kyoto University Graduate School of Energy Science, Gokasho, Uji 611-0011, Japan
| | - Katsumi Kondo
- Kyoto University Graduate School of Energy Science, Gokasho, Uji 611-0011, Japan
| | - T. Mizuuchi
- Kyoto University, Institute of Advanced Energy, Gokasho, Uji 611-0011, Japan
| | - F. Sano
- Kyoto University, Institute of Advanced Energy, Gokasho, Uji 611-0011, Japan
| | - K. Nagasaki
- Kyoto University, Institute of Advanced Energy, Gokasho, Uji 611-0011, Japan
| | - H. Okada
- Kyoto University, Institute of Advanced Energy, Gokasho, Uji 611-0011, Japan
| | - S. Kobayashi
- Kyoto University, Institute of Advanced Energy, Gokasho, Uji 611-0011, Japan
| | - K. Takahashi
- Kyoto University Graduate School of Energy Science, Gokasho, Uji 611-0011, Japan
| | - H. Shidara
- Kyoto University Graduate School of Energy Science, Gokasho, Uji 611-0011, Japan
| | - Y. Manabe
- Kyoto University Graduate School of Energy Science, Gokasho, Uji 611-0011, Japan
| | - M. Kaneko
- Kyoto University Graduate School of Energy Science, Gokasho, Uji 611-0011, Japan
| | - Y. Ohno
- Kyoto University Graduate School of Energy Science, Gokasho, Uji 611-0011, Japan
| | - T. Takamiya
- Kyoto University Graduate School of Energy Science, Gokasho, Uji 611-0011, Japan
| | - Y. Nishioka
- Kyoto University Graduate School of Energy Science, Gokasho, Uji 611-0011, Japan
| | - H. Yukimoto
- Kyoto University Graduate School of Energy Science, Gokasho, Uji 611-0011, Japan
| | - S. Nakazawa
- Kyoto University Graduate School of Energy Science, Gokasho, Uji 611-0011, Japan
| | - S. Nishio
- Kyoto University Graduate School of Energy Science, Gokasho, Uji 611-0011, Japan
| | - Y. Fukagawa
- Kyoto University Graduate School of Energy Science, Gokasho, Uji 611-0011, Japan
| | - M. Yamada
- Kyoto University Graduate School of Energy Science, Gokasho, Uji 611-0011, Japan
| | - T. Obiki
- Kyoto University, Institute of Advanced Energy, Gokasho, Uji 611-0011, Japan
| |
Collapse
|
39
|
Ogawa H, Nishimura N, Nishioka Y, Azuma M, Yanagawa H, Sone S. Adenoviral interleukin-12 gene transduction into human bronchial epithelial cells: up-regulation of pro-inflammatory cytokines and its prevention by corticosteroids. Clin Exp Allergy 2003; 33:921-9. [PMID: 12859448 DOI: 10.1046/j.1365-2222.2003.01702.x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
BACKGROUND One of the potential effects of IL-12 is to restore Th1/Th2 balance. Therefore, we investigated the possibility of developing a system for local delivery of IL-12 into the airways by examining protein expression in a human bronchial epithelial cell line (BEAS-2B) after adenoviral IL-12 gene transduction. The effects of dexamethasone on the gene-modified cells were also examined. METHODS Adenoviral vectors AxCAegfp and Ax1CIhp40ip35 were used to transduce enhanced green fluorescence protein and IL-12 genes, respectively, into BEAS-2B cells. Wild-type and IL-12 gene-transduced BEAS-2B cells were then incubated with or without dexamethasone, and concentrations of IL-12, IFN-gamma, IL-6, IL-8, granulocyte macrophage-colony stimulating factor and chemokines (TARC and RANTES) in the supernatant were measured by ELISA. IL-12 receptor expression was analysed by flow cytometry and RT-PCR. RESULTS The efficiency of transgene expression in BEAS-2B cells at a multiplicity of infection of 30 was approximately 80%. Gene-modified BEAS-2B cells produced biologically active IL-12, regardless of dexamethasone treatment. While IL-12 gene transduction led to increased production of IL-6 and IL-8 by BEAS-2B cells, expressions of these proteins were suppressed by dexamethasone. Addition of exogenous IL-12 failed to augment BEAS-2B cell IL-6 and IL-8 production, and IL-12 receptor expression by BEAS-2B cells was not detected. CONCLUSIONS Our findings suggest that adenoviral IL-12 gene transduction may be effective in inducing IL-12 expression in the airways, and could be a potential approach in the management of bronchial asthma.
Collapse
Affiliation(s)
- H Ogawa
- Department of Internal Medicine and Molecular Therapeutics, University of Tokushima, School of Medicine, Tokushima, Japan
| | | | | | | | | | | |
Collapse
|
40
|
Ishioka S, Sagae S, Sugimura M, Nishioka Y, Kobayashi K, Kudo R. Clinical factors and biomarkers which affect a new universal grading system for ovarian epithelial carcinoma. J Obstet Gynaecol Res 2001; 27:313-8. [PMID: 11794816 DOI: 10.1111/j.1447-0756.2001.tb01278.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
OBJECTIVE To detect clinical factors and biomarkers which affect a new grading system for ovarian epithelial cancer that was proposed by Shimizu et al. and to analyze the impact of those factors on malignant behaviors of the tumor. METHODS Review and scoring of specimens of paraffin embedded tissues of epithelial ovarian cancer were carried out according to the new universal grading system in 110 women who underwent initial treatments including the primary operation in our university hospital between January 1990 and June 1999. As biomarkers, expression of Bcl-2, Bax, Bcl-X, and the accumulation of P53 protein were also studied immunohistochemically. RESULTS This grading system functioned as a prognostic indicator. Five-year survivals of the patients was 77.6, 36.3, and 17.4%, for Grade 1, Grade 2, and Grade 3, respectively. The grade was also correlated with clinical stages, histologic subtypes, operative completeness, para-aortic lymph nodes metastasis, and the expression of Bax protein, with univariate analysis. Multivariate analysis revealed histological subtypes and para-aortic lymph nodes metastasis to be important factors which affected the grading system. CONCLUSION These results demonstrate that the new universal grading system is useful, and that this grading system might reflect potential of metastasis or dissemination of the ovarian cancer.
Collapse
Affiliation(s)
- S Ishioka
- Department of Obstetrics and Gynecology, Sapporo Medical University School of Medicine, Hokkaido, Japan
| | | | | | | | | | | |
Collapse
|
41
|
Suzuki Y, Yanagawa H, Nishioka Y, Nishimura N, Takeuchi E, Sone S. Efficient generation of dendritic cells from alveolar and pleural macrophages as well as blood monocytes in patients with lung cancer. Lung Cancer 2001; 34:195-205. [PMID: 11679178 DOI: 10.1016/s0169-5002(01)00234-3] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
In this study, we investigated the generation of dendritic cells (DCs) from blood monocytes and mature macrophages from untreated primary lung cancer patients. Blood monocytes were separated by adherence from blood mononuclear cells (MNC) from ten lung cancer patients and ten control subjects, and cultured for 7 days in medium with granulocyte/macrophage colony-stimulating factor (GM-CSF) plus interleukin (IL-) 4. In all cases examined, DCs with typical characteristics were obtained even in lung cancer patients after 7 days culture with these cytokines, and there was no significant difference in phenotype and stimulatory activity in allogeneic lymphocyte proliferation between DCs derived from monocytes from lung cancer patients and those from control subjects. Next, we examined whether alveolar and pleural macrophages in malignant pleural effusion separated by magnetic beads could differentiate to immunostimulatory DCs. Conventional culture conditions with GM-CSF and IL-4 did not induce efficient numbers of DCs from mature macrophages, whereas the addition of tumor necrosis factor-alpha (TNF-alpha) to GM-CSF and IL-4 effectively contributed to generate DCs. These findings suggest that both mature macrophages and blood monocytes from lung cancer patients could differentiate to DCs, and might be a useful source of DCs for immunotherapy.
Collapse
Affiliation(s)
- Y Suzuki
- Third Department of Internal Medicine, The University of Tokushima School of Medicine, Kuramoto-cho 3, Tokushima 770-8503, Japan
| | | | | | | | | | | |
Collapse
|
42
|
Hanibuchi M, Nishioka Y, Yanagawa H, Yano S, Parajuli P, Bando M, Sone S. Human interferon-gamma enhances expression of ganglioside GM2 on human lung cancer cells and their susceptibility for antiganglioside GM2 monoclonal antibody-dependent cellular cytotoxicity. Oncol Res 2001; 12:173-9. [PMID: 11341466 DOI: 10.3727/096504001108747657] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
Interferons are known to modulate several cellular functions by the induction of various proteins. In this study, we demonstrated that human interferon-gamma (HuIFN-gamma) enhanced the expression of ganglioside GM2 (GM2), which is a kind of tumor-associated antigen substantially expressed in human lung cancer and that human lung cancer cells expressing GM2 became more susceptible to anti-GM2 monoclonal antibody (mAb)-dependent tumor cell killing mediated by human effector cells after HuIFN-gamma treatment. GM2 expression on human lung cancer cells treated with or without HuIFN-gamma was measured by flow cytometry. The antibody-dependent cellular cytotoxicity (ADCC) activity was assessed by 4-h 51Cr release assay. HuIFN-gamma enhanced GM2 expression on human small-cell lung cancer (SCLC), SBC-3, and human non-small-cell lung cancer (NSCLC), A549 cells in a dose-dependent manner. The optimal concentration of HulIFN-gamma was 1,000 U/ml. The effect of HulFN-gamma reached maximum after 4 days of culture. HulFN-gamma did not have any effect to enhance the expression of other gangliosides in SBC-3 cells. No other cytokines used in this study modulated GM2 expression in SBC-3 cells. Anti-GM2 mAb-dependent ADCC activities induced by lymphocytes and monocytes were more potent against IFN-gamma-treated SBC-3 and A549 cells than nontreated cells. Taken together, HulFN-gamma combined with anti-GM2 mAb may be useful for immunotherapy against GM2-positive human lung cancer.
Collapse
Affiliation(s)
- M Hanibuchi
- Third Department of Internal Medicine, The University of Tokushima School of Medicine, Japan
| | | | | | | | | | | | | |
Collapse
|
43
|
Abstract
Dendritic cells (DC) are known to be the most potent APC and to stimulate antigen-specific T cell responses. Recently it was reported that murine DC were also capable of modulating the innate immunity by stimulating NK cells through cell-to-cell contact. In the present study, we examined whether human DC could affect NK activity. Both monocyte-derived and CD83(+) blood DC were tested. The addition of DC to cultures of CD56(+) cells resulted in the significant dose-dependent enhancement of the killing activity against various NK-sensitive targets. The resultant activity was comparable to that induced by optimal concentrations of various cytokines, including IL-2, IL-12, IL-15 and IFN-gamma. Interestingly, DC enhanced the cytotoxicity of CD3(-)CD56(+) NK cells, but not that of CD3(+)CD56(+) T cells. Experiments using transwells clearly demonstrated that the enhancement of NK activity by DC was mediated by soluble factors produced by DC. The culture supernatants of DC also stimulated NK activity. The treatment of both DC and their supernatants with anti-human IL-12 or IL-18 antibodies did not block the enhancement of NK cell-mediated cytolysis by DC, indicating that other factor(s) produced by DC were responsible for the enhancement of NK activity. These results suggest that human myeloid DC can modulate innate immunity by enhancing NK activity.
Collapse
Affiliation(s)
- Y Nishioka
- Third Department of Internal Medicine, University of Tokushima School of Medicine, Tokushima, Japan.
| | | | | | | |
Collapse
|
44
|
Hanibuchi M, Yano S, Nishioka Y, Yanagawa H, Miki T, Sone S. Immunological circumvention of multiple organ metastases of multidrug resistant human small cell lung cancer cells by mouse-human chimeric anti-ganglioside GM2 antibody KM966. Clin Exp Metastasis 2001; 18:353-60. [PMID: 11467766 DOI: 10.1023/a:1010941513570] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
serum against SBC-3/DOX cells to a similar extent compared with parental SBC-3 cells. Pretreatment of human effector cells with various cytokines induced further enhancement of the KM966-dependent ADCC against SBC-3/DOX cells. Intravenous injection of SBC-3 or SBC-3/DOX cells into natural killer (NK) cell-depleted severe combined immunodeficient (SCID) mice developed metastases in multiple organs (liver, kidneys and lymph nodes). Interestingly, SBC-3/DOX cells produced metastases more rapidly than SBC-3 cells, suggesting more aggressive phenotype of SBC-3/DOX cells than their parental cells in vivo. Systemic treatment with KM966, given on days 2 and 7, drastically inhibited the formation of multiple-organ metastases produced by both SBC-3 and SBC-3/DOX cells, indicating that KM966 can eradicate metastasis by SCLC cells irrespective of MDR phenotype. These findings suggest that the mouse-human chimeric KM966 targets the GM2 antigen, and might be useful for the immunological circumvention of multiple-organ metastases of refractory SCLC.
Collapse
Affiliation(s)
- M Hanibuchi
- Third Department of Internal Medicine, University of Tokushima School of Medicine, Japan
| | | | | | | | | | | |
Collapse
|
45
|
Nokihara H, Yano S, Nishioka Y, Hanibuchi M, Higasida T, Tsuruo T, Sone S. A new quinoline derivative MS-209 reverses multidrug resistance and inhibits multiorgan metastases by P-glycoprotein-expressing human small cell lung cancer cells. Jpn J Cancer Res 2001; 92:785-92. [PMID: 11473730 PMCID: PMC5926782 DOI: 10.1111/j.1349-7006.2001.tb01162.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Abstract
Development of distant metastases and acquired multidrug resistance (MDR) are major problems in therapy for human small cell lung cancer (SCLC). MS-209 is a novel quinoline compound, which reverses P-glycoprotein (P-gp)-mediated MDR. We previously reported that MS-209 reversed in vitro MDR of human SCLC (SBC-3 / ADM and H69 / VP) cells expressing P-gp. In the present study, we determined the therapeutic effect of MS-209 in combination with chemotherapy against multiorgan metastases of MDR SCLC cells. SBC-3 / ADM cells expressing P-gp were highly resistant to etoposide (VP-16), adriamycin (ADM), and vincristine (VCR) in vitro, compared with parental SBC-3 cells lacking P-gp expression. MS-209 restored chemosensitivity of SBC-3 / ADM cells to VP-16, ADM, and VCR in a dose-dependent manner in vitro. Intravenous injection with SBC-3 or SBC-3 / ADM cells produced metastatic colonies in the liver, kidneys and lymph nodes in natural killer (NK) cell-depleted severe combined immunodeficiency (SCID) mice, though SBC-3 / ADM cells more rapidly produced metastases than did SBC-3 cells. Treatment with VP-16 and ADM reduced metastasis formation by SBC-3 cells, whereas the same treatment did not affect metastasis by SBC-3 / ADM cells. Although MS-209 alone had no effect on metastasis by SBC-3 or SBC-3 / ADM cells, combined use of MS-209 with VP-16 or ADM resulted in marked inhibition of metastasis formation by SBC-3 / ADM cells to multiple organs. These findings suggest that MS-209 reversed the MDR of SBC-3 / ADM cells, but not SBC-3 cells, growing in the various organs, and inhibited metastasis formation in vivo. Therefore, this chemosensitizing agent, MS-209, may be useful for treatment of refractory SCLC patients with multiorgan metastases.
Collapse
MESH Headings
- ATP Binding Cassette Transporter, Subfamily B, Member 1/antagonists & inhibitors
- ATP Binding Cassette Transporter, Subfamily B, Member 1/biosynthesis
- Animals
- Antineoplastic Agents/pharmacology
- Antineoplastic Combined Chemotherapy Protocols/pharmacology
- Carcinoma, Small Cell/drug therapy
- Carcinoma, Small Cell/metabolism
- Carcinoma, Small Cell/secondary
- Doxorubicin/administration & dosage
- Doxorubicin/pharmacology
- Drug Resistance, Multiple
- Drug Screening Assays, Antitumor
- Etoposide/administration & dosage
- Etoposide/pharmacology
- Humans
- Lung Neoplasms/drug therapy
- Lung Neoplasms/metabolism
- Lung Neoplasms/pathology
- Male
- Mice
- Mice, SCID
- Neoplasm Metastasis
- Quinolines/administration & dosage
- Quinolines/pharmacology
- Vincristine/administration & dosage
- Vincristine/pharmacology
- Xenograft Model Antitumor Assays
Collapse
Affiliation(s)
- H Nokihara
- Third Department of Internal Medicine, University of Tokushima School of Medicine, Tokushima 770-8503, Japan
| | | | | | | | | | | | | |
Collapse
|
46
|
Nishimura N, Nishioka Y, Shinohara T, Ogawa H, Yamamoto S, Tani K, Sone S. Novel centrifugal method for simple and highly efficient adenovirus-mediated green fluorescence protein gene transduction into human monocyte-derived dendritic cells. J Immunol Methods 2001; 253:113-24. [PMID: 11384673 DOI: 10.1016/s0022-1759(01)00360-x] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
Dendritic cells (DC) are professional antigen-presenting cells in the immune system. Gene transduction of DC with tumor-associated antigen (TAA) or other genes that enhance the immune reaction has been considered theoretically useful for DC-based immunotherapy. However, gene transduction of DC generated from human peripheral blood monocytes has been difficult due to its low efficiency, even when adenoviral vector was used at high multiplicity of infection (MOI). In the present study, we examined the effect of centrifugal force to enhance efficiency of adenovirus-mediated gene transduction into human monocyte-derived DC at various rotor speeds at various temperatures for various times. We judged the transduction efficiency using enhanced green fluorescence protein (EGFP)-expressing adenoviral vector, and the best condition for centrifugal transduction was determined as 2000 x g at 37 degrees C for 2 h at an MOI of 10 or greater. At an MOI of 50 without centrifugation, the gene transduction efficiency was about 66% and mean fluorescence intensity (MFI) of EGFP expression was about 150 (at 37 degrees C for 2 h). With centrifugal transduction (2000 x g at an MOI of 50 at 37 degrees C for 2 h), 86% or more DC were gene-modified, and especially, MFI of EGFP expression was highly enhanced (MFI: about 3100 or greater). Centrifugally gene-transduced DC were not damaged and were thoroughly functional as measured by mixed lymphocyte reaction (MLR). The centrifugal method was also applicable to human monocytes and K562 cells. The centrifugal transduction method with adenoviral vector might be helpful for the generation of gene-modified DC.
Collapse
Affiliation(s)
- N Nishimura
- Third Department of Internal Medicine, School of Medicine, University of Tokushima, Kuramoto-cho 3, 770-8503, Tokushima, Japan
| | | | | | | | | | | | | |
Collapse
|
47
|
Nishioka Y, Ogushi F, Sone S. [Idiopathic interstitial pneumonia, idiopathic pulmonary fibrosis]. Ryoikibetsu Shokogun Shirizu 2001:239-44. [PMID: 11269067] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/19/2023]
Affiliation(s)
- Y Nishioka
- Third Department of Internal Medicine, University of Tokushima, School of Medicine
| | | | | |
Collapse
|
48
|
Abstract
Much effort has been made to achieve lymphatic targeting of drugs using colloidal carriers. This paper reviews the recent progress in the development of biodegradable nanoparticulate systems, including nanospheres, emulsions, and liposomes. The major purpose of lymphatic targeting is to provide an effective anticancer chemotherapy to prevent the metastasis of tumor cells by accumulating the drug in the regional lymph node via subcutaneous administration. The objectives of lymph targeting also involve the localization of diagnostic agents to the regional lymph node to visualize the lymphatic vessels before surgery, and the improvement of peroral bioavailability of macromolecular drugs, like polypeptides or proteins, which are known to be selectively taken up from the Peyer's patch in the intestine. Nanocapsules, which are ultrafine oily droplet-coated polymeric substances, are probably one of the most promising candidates of colloidal carriers. Surface engineering by the interfacial deposition method can provide a suitable size distribution and necessary surface characteristics to the nanocapsules. Our recent in vivo study proved that polyisobutylcyanoacrylate nanocapsules showed enhanced accumulation of drug in the lymph node, compared with other carriers such as emulsions and liposomes.
Collapse
Affiliation(s)
- Y Nishioka
- Department of DDS Research, Discovery Research Laboratory, Tanabe Seiyaku Co. Ltd., 16-89 Kashima 3-chome, Yodogawa-ku, Osaka, 532-8505 Japan
| | | |
Collapse
|
49
|
Nishimura N, Nishioka Y, Shinohara T, Sone S. Enhanced efficiency by centrifugal manipulation of adenovirus-mediated interleukin 12 gene transduction into human monocyte-derived dendritic cells. Hum Gene Ther 2001; 12:333-46. [PMID: 11242526 DOI: 10.1089/10430340150503966] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Transduction of dendritic cells (DCs) with genes encoding tumor-associated antigen or with other genes that enhance immune reaction has been theorized to be potentially useful for enhancing the efficiency of DC-based immunotherapy. However, gene transduction of DCs generated from human peripheral blood monocytes has been of limited use because of the low efficiency. Here, we report that the efficiency of in vitro adenovirus-mediated gene transduction into human monocyte-derived DCs can be dramatically enhanced by centrifugation. The best conditions for centrifugal gene transduction were determined to be as follows: 2000 x g at 37 degrees C for 2 hr at a multiplicity of infection (MOI) of 10 or greater. By this centrifugal method, approximately 88 and 70% of DCs were gene transducible at an MOI of 50 and 10, respectively. Functional analysis showed that DCs transduced with human interleukin 12 (IL-12)-expressing adenoviral vector under the optimal conditions of centrifugation stably produced IL-12 protein at high levels (8.1 ng/10(6) cells/48 hr). IL-12 gene-modified DCs (DC/IL-12) displayed a more mature phenotype than nontransduced DCs, as judged by decreased expression of CD1a and increased expression of CD83, B7.1 (CD80), B7.2 (CD86), and MHC class I and II molecules. DC/IL-12 showed a high phagocytic ability similar to nontransduced DCs and were significantly superior to control DCs in the stimulation of autologous and allogeneic T lymphocyte responses. The centrifugal transduction method with adenoviral vector might be useful for efficient generation of gene-modified DCs because it is very simple, highly efficient, reproducible, and not cytopathic. IL-12 gene-modified human DCs may be therapeutically useful as a good adjuvant in DC-based immunotherapy.
Collapse
Affiliation(s)
- N Nishimura
- Third Department of Internal Medicine, School of Medicine, University of Tokushima, Kuramoto-cho 3, Tokushima 770-8503, Japan
| | | | | | | |
Collapse
|
50
|
Kanematsu T, Ohgushi F, Ogawa H, Nishioka Y, Shinohara T, Yanagawa H, Sone S. [Bullous sarcoidosis--a case report]. Nihon Kokyuki Gakkai Zasshi 2001; 39:117-21. [PMID: 11321822] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/19/2023]
Abstract
A 37-year-old man was admitted to our hospital complaining of dry cough and dyspnea. His chest radiographs showed severe bullous changes in the upper lobes and scattered small nodules in the lower. During the course of further examination, a spontaneous left pneumothorax developed in the lung, and video-assisted thoracic surgery was performed to remove a bulla. Multiple noncaseous granulomas were seen and sarcoidosis was diagnosed. Here we report a case of pathologically investigated bullous sarcoidosis, which is rarely seen to generate bullae due to granulomatous lesions. Therefore, it is important to consider sarcoidosis in making a differential diagnosis when a diffuse lung disease with cystic change is encountered.
Collapse
Affiliation(s)
- T Kanematsu
- Third Department of Internal Medicine, University of Tokushima, 2-5-1 Kuramoto-cho, Tokushima, Japan 770-8503
| | | | | | | | | | | | | |
Collapse
|